Clinical Trials Logo

Pediculosis clinical trials

View clinical trials related to Pediculosis.

Filter by:

NCT ID: NCT00731718 Completed - Pediculosis Clinical Trials

Control of Head Lice Infestations in Children and Adults

Start date: June 2007
Phase: N/A
Study type: Interventional

The goal of this study is to see if heated air will kill head lice and their eggs. The treatment visit is approximately 1 hour long with a follow up phone call.

NCT ID: NCT00545753 Completed - Pediculosis Clinical Trials

Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice

Start date: September 2007
Phase: Phase 3
Study type: Interventional

A comparative safety and efficacy study of NatrOVA Creme Rinse - 1% versus NIX Creme Rinse, under actual use conditions in subjects 6 months of age or greater who are infested with Pediculosis capitis (human head lice).

NCT ID: NCT00381082 Completed - Pediculosis Clinical Trials

A Randomised, Assessor-Blind, Comparative Efficacy Clinical Trial of 3 Pediculicides.

Start date: September 2004
Phase: Phase 2/Phase 3
Study type: Interventional

Objective To compare the cure rates (defined as the complete absence of live lice, adults or nymphs, as diagnosed by wet-combing of three Australian approved head lice products for the treatment of primary school children with head lice infestation. The study design will be randomised and assessor-blind using three comparative parallel treatment groups. The study population will consist of Queensland state primary school children (up to Year 7) with live head lice (adults or nymphs) on the hair or scalp who have not used any head lice product in the four weeks prior to the study.

NCT ID: NCT00207753 Completed - Hookworm Infection Clinical Trials

Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections

Start date: February 2005
Phase: N/A
Study type: Interventional

The aim of this study is to compare the efficacy and impact on growth of two drug treatments against intestinal worms in schoolchildren from a rural area of Guatemala. According to the World Bank, these intestinal worms are one of the top causes of childhood health problems in many areas of the developing world (The World Bank, 1993). Infected children are more likely to have inadequate nutrition due to the worm infections and are more likely to be shorter in height and weigh less than children who are not infected. After collecting height and weight information, we will split the children into two groups. One group will receive albendazole and the other group will receive combined albendazole/ivermectin. Both groups will be receiving albendazole, the current standard of care treatment. Ivermection is expected to improve efficacy and nutritional benefit as well as add increased scope of treatment for the worm Strongyloides, and ectoparasites such as scabies and head lice. Both treatment regimens and the combination have been used millions of times in the developing world and are safe to use. Co-administration of drugs would be a more efficient use of the opportunity to access schoolchildren and provide deworming treatment.